Literature DB >> 9416782

The endogenous mu-opioid agonists, endomorphin 1 and 2, have vasodilator activity in the hindquarters vascular bed of the rat.

H C Champion1, J E Zadina, A J Kastin, P J Kadowitz.   

Abstract

Endomorphin 1 and endomorphin 2 are newly-discovered endogenous ligands for the mu-opioid receptor. In the present study, responses to intra-arterial injections of endomorphin 1 and 2 were investigated in the hindquarters vascular bed of the rat. Under constant-flow conditions, endomorphin 1 and 2 induced dose-dependent decreases in hindquarters perfusion pressure when injected in doses of 3-100 nmol into the hindquarters perfusion circuit. Vasodilator responses to endomorphin 1 and 2 and met-enkephalin were attenuated by the opioid receptor antagonist naloxone (2 mg/kg i.v.) at a time when vasodilator responses to isoproterenol were not altered. In terms of relative vasodilator activity, endomorphin 1 and 2 were similar to ATP, 100-fold less potent than isoproterenol, and 10,000-fold less potent than acetylcholine. These data demonstrate that endomorphin 1 and 2 have significant naloxone-sensitive vasodilator activity in the hindquarters vascular bed of the rat.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9416782     DOI: 10.1016/s0024-3205(97)01029-1

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

Review 1.  Engineering endomorphin drugs: state of the art.

Authors:  Lawrence H Lazarus; Yoshio Okada
Journal:  Expert Opin Ther Pat       Date:  2012-01-04       Impact factor: 6.674

2.  Endomorphin-1 induced desensitization and down-regulation of the recombinant mu-opioid receptor.

Authors:  C Harrison; D J Rowbotham; D K Grandy; D G Lambert
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

3.  The effects of endomorphin-1 and endomorphin-2 in CHO cells expressing recombinant mu-opioid receptors and SH-SY5Y cells.

Authors:  C Harrison; S McNulty; D Smart; D J Rowbotham; D K Grandy; L A Devi; D G Lambert
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.